LENZ Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has approved its flagship ophthalmic drug, VIZ-Z™ (aceclidine ophthalmic solution), for the treatment of presbyopia—a common age-related condition that reduces the ability to focus on nearby objects. According to the official pre... The approval is based on results from the Phase 3 INSIGHT clinical program, which enrolled over 1,200 patients and demonstrated that a single daily dose provided sustained improvement in near vision throughout the day, with an onset of effect within 30 minutes. The trials also reported a favorable safety profile, with the most common adverse events being mild and transient. Presbyopia affects approximately 128 million Americans, typically starting in the early-to-mid 40s and progressing with age. Traditional solutions have been limited to optical corrections or surgical interventions. LENZ positions VIZ-Z as a transformative option for patients seeking flexibility, discretion, and freedom from visual aids during daily activities. Eef Schimmelpennink, CEO of LENZ Therapeutics, highlighted that the FDA approval marks a “defining moment” for the company, reinforcing its commitment to addressing unmet needs in ophthalmology. LENZ plans to launch VIZ-Z in the U.S. market in Q4 2025, supported by an educational campaign aimed at eye-care professionals and consumers. The company is also advancing additional ophthalmic programs in its pipeline, targeting conditions such as myopia progression and ocular surface disease. With the approval of VIZ-Z, LENZ enters a new commercial phase, aiming to establish a strong presence in the rapidly evolving presbyopia treatment market.